Background: Therapeutic mammaplasty, which combines breast reduction and mastopexy techniques with tumour excision, may extend the boundaries of breast-conserving surgery and improve outcomes for patients, but current practice is unknown and high-quality outcome data are lacking. This prospective multicentre cohort study aimed to explore the practice and short-term outcomes of the technique. Conclusion: Therapeutic mammaplasty is a safe and effective alternative to mastectomy or standard breast-conserving surgery. Further work is required to explore the impact of the technique on quality of life, and to establish cost-effectiveness.
Introduction
Breast-conserving surgery (BCS) with adjuvant radiotherapy is an established treatment for early breast cancer 1, 2 .
Therapeutic mammaplasty (TM) describes 'the oncoplastic application of breast reduction and mastopexy techniques to treat selected breast cancers by BCS' 9, 10 . These techniques effectively extend the boundaries of traditional BCS by allowing adequate resection of larger tumours in women with medium to large breasts without compromising cosmetic outcome 11 -14 . They provide an alternative to mastectomy with or without reconstruction in patients with ptotic breasts 9, 15 and may improve outcomes for women with large breasts in whom standard BCS followed by radiotherapy may be associated with lymphoedema, fibrosis and chronic pain 16 . Despite the widespread adoption of these techniques into routine practice, there is limited high-quality evidence to support benefits of this approach. TM procedures are more complex than standard BCS, with potential resource implications. Although complication rates and oncological safety have been reported in the literature 16 -24 the majority of published studies are retrospective, single-centre 16, 22 -24 , often single-surgeon case series with limited follow-up. Many are poorly designed and reported, with inconsistent end-points 25 that limit cross-study comparison and meaningful data synthesis. Several recent systematic reviews 26 -34 have highlighted the paucity of high-quality clinical, oncological and cosmetic outcome data, and emphasized the urgent need for well designed prospective studies to establish the indications and outcomes of TM to inform best practice.
Although RCTs provide the best evidence for the effectiveness of an intervention, they are largely inappropriate in this context. A high-quality prospective multicentre cohort study exploring the practice and outcomes of these techniques is therefore essential to support the safe practice of TM, generate guidelines, guide decision-making and inform health policy.
The aim of this study was to describe the current practice of TM, including indications and techniques used, complication and incomplete tumour excision rates, and the impact of TM on the time to delivery of adjuvant therapy. Secondary aims were to identify risk factors associated with complications and incomplete excision, and to develop a network of surgeons performing the technique and engage them in the need for evaluation.
Methods

Study design and participants
All breast and plastic surgical units performing TM were invited to participate in this multicentre prospective cohort study through the UK breast and plastic surgical trainee research collaborative network (Mammary Fold Academic and Research Collaborative and the Reconstructive Surgery Trials Network) and relevant professional associations (Association of Breast Surgery and British Association of Plastic, Reconstructive and Aesthetic Surgeons) 35 .
Consecutive women undergoing TM at participating units between 1 September 2016 and 30 June 2017 were recruited prospectively to the study. TM was defined as 'the application of breast reduction or mastopexy techniques, including removal of skin to reduce the skin envelope, to treat invasive or ductal carcinoma in situ (DCIS) using BCS' 9, 10 . Patients undergoing standard BCS not involving reduction of the skin envelope, level one oncoplastic techniques involving glandular remodelling only or BCS with volume replacement techniques such as local perforator (for example thoracodorsal artery perforator, or lateral intercostal artery perforator (LiCAP) flaps or latissimus dorsi miniflaps) were excluded. Patients undergoing surgery for benign disease and those having a mastectomy with or without immediate breast reconstruction were also excluded.
Demographic, preoperative planning, operative and oncological data were collected prospectively for all patients, as described previously 35 . Recommended adjuvant treatments were decided at postoperative multidisciplinary team (MDT) meetings, and date of commencement of adjuvant treatment was taken from appropriate on-line hospital systems or case-note review. Complications, readmissions and reoperations at 30 days were collected prospectively by clinical review or retrospective review of case notes in patients not attending for follow-up. All data were collected by members of the surgical team and managed using REDCap data capture software (http://www.projectredcap.org/) 36, 37 .
This study was classified as service evaluation/clinical audit by the NHS Health Research Authority Decision Tool (http://www.hra-decisiontools.org.uk/research/index .html). Individual patient consent was not needed, but each participating centre was required to obtain local clinical governance approvals before commencing patient recruitment.
Primary outcomes
The primary outcome was unplanned reoperation for local complications within 30 days of the TM procedure. This included reoperation for any complications of the TM and/or contralateral symmetrizing procedure, but not additional surgery for oncological reasons, including the need for re-excision of margins, completion mastectomy or axillary clearance. This outcome was selected based on Quality Criterion 16 from Oncoplastic Breast Surgery: Guidelines for Best Practice 38 , which states that less than 5 per cent of patients should require return to theatre for complications following oncoplastic breast surgery. Specific outcomes of interest included: haematoma requiring surgical evacuation; infection requiring surgical drainage or debridement; skin necrosis including T junction breakdown requiring surgical debridement; nipple necrosis or complete nipple loss necessitating surgical debridement; and wound dehiscence requiring return to theatre for resuturing. Full definitions of complications used in the study have been reported previously 35 .
Secondary outcomes
Secondary outcomes reflected current best practice 38 and National Institute for Health and Care Excellence guidelines 39 , and included readmission to hospital, incomplete tumour excision requiring further surgery, and time to delivery of adjuvant therapy 35 . Readmission to hospital was defined as any readmission after discharge for local or systemic complications of surgery, as defined in the study protocol 35 , within 30 days of the index procedure. Incomplete tumour excision was defined as invasive tumour or DCIS at, or close to, the resection margin requiring further surgery (re-excision of margins or completion mastectomy) as defined by local MDT criteria. Re-excision of margins was defined as return to theatre for removal of additional tissue in a second operation due to one or more involved/positive margins. Completion mastectomy was defined as the complete removal of remaining breast tissue as elected by MDT decision or patient choice. Time to adjuvant therapy was defined as the time in days from the TM (or last oncological surgery, if further surgery was required) to the first adjuvant treatment (first chemotherapy dose or first fraction of radiotherapy).
Data quality assurance
For quality assurance (QA) purposes, the principal investigator at each site was requested independently to validate 5-10 per cent of the data entered from their unit. The validation process involved checking and confirming that all entered data for the selected patients were correct. If concordance between the number of cases submitted on REDCap and those identified independently was less than 90 per cent, the unit's data were excluded from the final analysis. This was consistent with QA procedures used in other collaborative studies 40 .
Statistical analysis
Descriptive summary statistics were calculated for each variable to describe the practice and outcomes of TM. Categorical data were summarized by counts and percentages, and continuous data by median, i.q.r. and range.
Univariable logistic regression analysis was used to explore clinicopathological variables hypothesized to be associated with the outcomes of interest. For complications, this included patient and procedure-related variables: patient age, smoking status, BMI, diabetes, co-morbidities, ASA grade, neoadjuvant chemotherapy, grade and experience of operating surgeon, type of skin incision, unilateral versus bilateral surgery, axillary surgery performed, specimen weight, drain use and duration of surgery. For incomplete excision, variables considered were: patient age, neoadjuvant chemotherapy, maximum preoperative tumour size, preoperative multifocality and localization, specimen imaging (yes versus no), invasive disease (versus DCIS), positive nodal status (N0 versus N1/N2), positive human epidermal growth factor receptor 2 status, positive oestrogen receptor status, ductal versus lobular invasive disease on postoperative pathological examination, grade of invasive disease on postoperative pathological examination, screening (versus symptomatic) and specimen weight. Variables with P < 0⋅100 were carried forward to a multivariable model to identify any independent risk factors for each outcome. P-values < 0⋅050 in the multivariable analysis were considered to be strongly associated with the outcome. All univariable and multivariable analyses had standard errors clustered by centre.
Time to adjuvant therapy was calculated for the cohort as a whole and for patients with and without postoperative complications. Kaplan-Meier analyses, univariable Cox survival models (with standard errors clustered by centre) and the log rank test were then used to determine whether complications impacted on time to delivery of adjuvant therapy.
Stata ® 15 (StataCorp, College Station, Texas, USA) was used for all analyses.
Results
Between 1 September 2016 and 30 June 2017, 898 patients were entered onto the REDCap database from 50 units across the UK (48 units) and Italy (2 units). Of these, eight patients underwent TM performed outside the study period, five patients received symmetrizing reduction surgery only, and five records did not provide any details of the patients or surgery performed; these 18 patients were excluded. Some 880 patients undergoing 899 TM procedures were thus included in the analysis. Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.) (range). n.r., Not reported.
Patient demographics
Patient demographics are summarized in Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.) (range). †More than one indication or treatment option could be given per patient. n.r., Not reported; DCIS, ductal carcinoma in situ; TM, therapeutic mammaplasty. Table 2 summarizes preoperative planning and surgical decision-making for TM. Tumours were a median of 24 (range 2-120) mm on preoperative imaging, with the Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.) (range). n.r., Not reported; TM, therapeutic mammaplasty; NAC, nipple-areola complex; WLE, wide local excision. The most common indication for TM was to avoid an anticipated poor cosmetic outcome associated with standard BCS (702 procedures, 78⋅1 per cent), but 379 patients (42⋅2 per cent) were offered the technique as an alternative to mastectomy. Quality-of-life benefits and avoidance of the sequelae of radiotherapy in large breasts were less commonly cited indications ( Table 2 ). Two-thirds of patients (590, 65⋅6 per cent) were offered standard BCS as an alternative surgical approach. For the remainder, the only alternative option was mastectomy alone (375, 41⋅7 per cent) or with immediate implant-based (270, 30⋅0 per cent) or autologous (231, 25⋅7 per cent) reconstruction. One-third of patients (283, 32⋅2 per cent) were offered contralateral symmetrization at the time of the TM procedure.
Preoperative tumour assessment and treatment planning
Operative techniques
Of the 880 patients, 562 (63⋅9 per cent) underwent a unilateral TM procedure with no simultaneous contralateral surgery, 284 (32⋅3 per cent) had a unilateral TM and simultaneous contralateral symmetrizing reduction or mastopexy, five (0⋅6 per cent) had a unilateral TM and a contralateral mastectomy with or without immediate reconstruction, and 19 (2⋅2 per cent) underwent bilateral TM procedures ( Table 3 ). The median duration of surgery was 110⋅5 (range 39-420) min, and the majority of procedures (771, 85⋅8 per cent) were performed by a consultant surgeon with significant experience (more than 25 procedures) in performing this technique. Two-thirds of lesions (600, 66⋅7 per cent) required preoperative localization, of which 170 (18⋅9 per cent) involved the use of bracketing wires or equivalent.
A wide range of different surgical approaches and techniques were used ( Table 3) . Wise-pattern skin incisions were the most common (429, 47⋅7 per cent) with periareolar or circumareolar approaches (232, 25⋅8 per cent) and vertical scar techniques (135, 15⋅0 per cent) used less frequently. In most TM procedures the nipple was preserved, using a central mound (225, 27⋅2 per cent), inferior (204, 24⋅6 per cent) or superiomedial (201, 23⋅4 per cent) pedicle. Wide local excision specimens had a median weight of 83 (range 6-1545) g, and adequacy of tumour excision was confirmed in 804 cases (89⋅4 per cent), most commonly using intraoperative specimen radiography (785, 87⋅3 per cent). Total TM excision weights ranged from 5 to 2522 (median 126⋅5) g, and drains were used in one-third of procedures (296, 32⋅9 per cent). Symmetrizing reductions were most likely to be performed using a Wise-pattern skin incision (232 of 284, 81⋅7 per cent) and a superiomedial (112 of 284, 39⋅4 per cent) or inferior (105 of 284, 37⋅0 per cent) nipple pedicle. The median reduction in weight was 320 (range 0-2477) g. The TM procedure was performed as a day case in 351 patients (39⋅9 per cent), and 232 (26⋅4 per cent) went home the day after surgery as a 23-h stay.
Reoperation and readmission for surgical complications
Twenty-five patients (2⋅8 per cent) required reoperation for a complication of the TM, although only 12 (1⋅4 per cent) were readmitted. In total, 205 patients (23⋅3 per cent) experienced at least one postoperative complication within the first 30 days after surgery. These were generally minor and managed on an outpatient basis; they included infections requiring oral antibiotics (70, 8⋅0 per cent) and wound healing problems managed conservatively with dressings (skin TM procedures performed n = 899
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Fourth procedure performed n = 1 Re-excision of margins n = 1 Table S1 , supporting information). Univariable analysis identified smoking, obesity, ASA grade, surgical experience, Wise-pattern skin incisions, bilateral surgery, specimen weight and the use of drains as risk factors associated with postoperative complications (Table 4) . Smoking, obesity, higher ASA grade, a less experienced surgeon and a Wise-pattern skin incision remained strongly associated with postoperative complications in the multivariable model. Duration of procedure was associated with complications in the univariable analysis, but as only 44⋅5 per cent of records contained this variable it was not included in the multivariable analysis.
Re-excision and completion mastectomy rates
The median pathological tumour size was 24⋅5 (i.q.r. Values in parentheses are *percentages and †95 per cent confidence intervals. DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2.
presented according to completeness or incompleteness of resection margins are summarized in Table 5 . Incomplete excision according to local criteria was reported for 132 procedures (14⋅7 per cent). Tumours with a positive margin were more likely to be multifocal (59 of 132 (44⋅7 per cent) versus 133 of 744 (17⋅9 per cent) for clear margins) and larger (median (i.q.r.) 39 (25-54) versus 23 (15-34) mm respectively). Management of incomplete excision in the study cohort is shown in Fig. 1 . Re-excision of margins was performed successfully in 68 cases, giving an overall breast conservation rate of 90⋅3 per cent (812 of 899). Completion mastectomy with or without immediate breast reconstruction was required in 43 patients (4⋅9 per cent) during the study, with a further eight patients planned for surgery following completion of adjuvant chemotherapy. The completion mastectomy rate was therefore 5⋅7 per cent (51 of 899) (Fig. 1) .
Univariable analysis identified maximum preoperative tumour size and preoperative assessment of multifocality as potential risk factors for incomplete excision ( Table 6 ). Both variables remained strongly 
Time to adjuvant therapy
Adjuvant treatment recommendations are summarized in Table S2 (supporting information). Adjuvant chemotherapy was recommended for 273 patients (31⋅0 per cent), of whom 228 (83⋅5 per cent) accepted treatment, and adjuvant radiotherapy was recommended for 794 patients (90⋅2 per cent). A total of 811 patients (92⋅2 per cent) accepted either postoperative chemotherapy and/or radiotherapy, and the median time from last oncological surgery to first adjuvant treatment was 54 (i.q.r. 42-66) days. There was no significant difference in time to start of adjuvant therapy for women with versus those without postoperative complications (odds ratio 0⋅88, 95 per cent c.i. 0⋅76 to 1⋅03; P = 0⋅109) (P = 0⋅147, log rank test) (Fig. 2) .
Discussion
TM may provide women with a safe alternative to mastectomy or offer improved cosmetic and quality-of-life outcomes compared with standard BCS, but high-quality evidence to support the safety and effectiveness of the technique is lacking 26, 27 . RCTs comparing TM with other techniques are largely inappropriate due to patient and surgeon preference, as well as mounting evidence suggesting long-term survival benefits for patients undergoing BCS and radiotherapy compared with mastectomy 41 -43 . This large prospective multicentre cohort study assessed current practice and short-term outcomes of the technique and provided 'real world' data from 50 centres regarding complications, rates and management of incomplete excision, and impact of TM procedures on the delivery of adjuvant therapy.
Although most women are offered TM to avoid poor cosmetic outcomes associated with standard BCS, over 40 per cent are offered TM to avoid mastectomy. Recent work comparing the outcomes of women undergoing TM and those undergoing mastectomy and immediate breast reconstruction suggests that TM may be associated with fewer complications 44 and better body image, function and quality of life than mastectomy and reconstruction 45 . The majority of women undergoing TM in the present study had a high BMI and co-morbidities that may have made them unsuitable or high risk for immediate breast reconstruction, and the procedure may have particular quality-of-life benefits for this group of patients. TM appears to be a specialist procedure as it is performed predominantly by consultant surgeons with significant experience of the technique. Although Wise-pattern mammaplasties were the most common procedures, a wide range of incisions and nipple pedicles were used. The varied techniques encompassed by TM mirror the dominant methods of breast reduction surgery, but are likely also to reflect tailoring of approach to the tumour and patient as well as surgeon preference and experience. Simultaneous contralateral symmetrizing reduction/mastopexy procedures were performed in only one-third of patients. Reasons for this were not addressed but may include patient or surgeon preference or local funding issues, but given the potential impact that delayed symmetrization may have on quality of life, with little if any improvements in overall symmetry, the reasons are worthy of further study.
Two-thirds of all TM procedures were performed either as a day case or with a 23-h stay, consistent with the length of stay required for standard BCS or mastectomy. Major complication rates were low, with less than 3 per cent of patients requiring reoperation for a complication of the TM and/or symmetrizing procedure, significantly lower than the 5 per cent recommended in oncoplastic surgery guidelines 38 . Complications were associated with smoking, high BMI, Wise-pattern skin incisions, ASA grade and surgeon experience, but not with contralateral symmetrizing surgery. Overall, 811 women (92⋅2 per cent) required adjuvant chemotherapy and/or radiotherapy, and the median time to adjuvant therapy was 54 days. This was not affected by complications and the interval is concordant with that of other studies of different surgical approaches 46 . TM does not therefore affect time to start adjuvant therapy.
Median pathological tumour size was 24⋅5 mm, but more than 20 per cent of excised lesions were larger than 40 mm, the traditional maximum size for standard BCS. Complete tumour excision, as defined by local MDT criteria, was achieved in 744 (82⋅8 per cent) of the 899 TM procedures, and a further 68 (7⋅6 per cent) complete excisions were obtained following one or more margin re-excisions, giving an overall breast conservation rate of 90⋅3 per cent. A mastectomy was ultimately required for only 51 lesions (5⋅7 per cent), and 20 of these (39 per cent) also involved immediate reconstruction. Large preoperative tumour size and multifocality were the only factors associated with incomplete excision in the multivariable model. This and the rate of re-excision are consistent with other studies of standard BCS 47, 48 , but in these studies the median tumour size was almost 10 mm smaller and the proportion of T2 tumours 25 per cent less than in the present study. The implication is that TM can achieve similar complete excision rates for large cancers as those attained by simple BCS techniques for small cancers.
The 'real world' outcome data generated from the multicentre TeaM (Therapeutic Mammaplasty) study are consistent with complication and re-excision rates reported in other series of oncoplastic surgery in which TM formed a part of the oncoplastic approach 27, 29, 34 . The most recent review 49 of ten large studies found complication rates ranging between 8⋅9 and 24⋅6 per cent. It is not clear whether these rates were per breast or per patient, but the present complication rate of 20⋅1 per cent per breast and 23⋅3 per cent per patient are broadly comparable. Incomplete excisions were reported in between 5⋅8 and 18⋅9 per cent of patients in these studies, leading to completion mastectomy rates of 2⋅9-12⋅5 per cent 49 . Here, incomplete excision occurred in less than 15 per cent of cases and the completion mastectomy rate was less than 6 per cent. While this is reassuring, such comparisons may not be entirely valid owing to the heterogeneity of procedures included in these studies 49 and the lack of consistency of the outcomes assessed 25 . Many studies and subsequently systematic reviews have reported outcomes of 'oncoplastic breast conservation'. This term is often used to describe a wide range of volume replacement (such as LiCAP flaps) and volume displacement techniques and procedures, ranging in complexity from a small amount of glandular remodelling to oncoplastic breast reductions, which are not directly comparable. A number of classification systems have been proposed, most notably Clough's bilevel classification 50 , but standard adoption of an agreed terminology is a major barrier to high-quality comparable research 27, 51, 52 . Recently, attempts at standardization have been proposed, but terminology and algorithms for decision-making are complex and the success of this approach is yet to be determined 53 . Agreement regarding the need for standardized outcome assessment, including standard definitions of complications and quality-of-life assessments using validated patient-reported outcome measures, however, must be a priority if future research in oncoplastic surgery is to be meaningful 52 . The recently developed core outcome set for reconstructive breast surgery is one way by which this may be achieved 54 .
This study has provided much needed prospective multicentre evidence for the short-term clinical safety and effectiveness of TM, but it has several limitations that require consideration. The main limitation is that patient-reported, cosmetic and long-term oncological outcomes of the TM technique were not considered. Although this is a significant limitation, one of the main aims of the study was to define current practice to inform the design and conduct of a future definitive research study, and to develop a network of centres performing TM to participate in the project. Furthermore, the existing cohort will be used to explore long-term oncological outcomes in a future data-linkage study, to provide added value. Well designed prospective cohort studies incorporating validated patient-reported outcome measures such as the BREAST-Q 55 , robust assessments of cosmetic outcome and appropriate health economic assessments may provide the best evidence of TM effectiveness.
This study collected data from 50 centres; it is possible that participating units were high-volume, highly specialist centres and the outcomes reported here are therefore not representative of those seen at lower-volume centres. However, the 48 UK centres included represent approximately one-third of all breast units in the country 56 , and the similarity of the outcomes with those in the published literature suggests that this is not the case. The observational study design introduces the possibility of bias, but several steps were taken to minimize this, including: publishing the study protocol a priori; providing clear inclusion and exclusion criteria, and ensuring participating units recruited consecutive patients; developing standardized outcome definitions and where possible using 'hard' outcomes such as reoperation, margin positivity and treatment start dates that are unambiguous and not open to interpretation. Despite this, the authors acknowledge that the cohort is heterogeneous and a range of procedures and techniques were included, but this heterogeneity is itself an important finding in terms of informing future studies. As this was a trainee collaborative study, the quality of the data could be questioned. Robust quality assurance processes, however, were used and no centre was excluded because of concerns regarding data completeness or accuracy.
The TeaM study adds significantly to the evidence base in oncoplastic breast surgery and provides much needed data to inform decision-making and future research. This preliminary work will ensure that any future study reflects current practice and addresses issues that are important to patients and the reconstructive community.
